Vertex Pharmaceuticals Incorporated (VRTX) announced today that a combination therapy of two of its drugs used for treating cystic fibrosis has yielded statistically favorable results in its late-stage clinical trials. Upon approval, it would be marketed to treat cystic fibrosis, a genetic condition that afflicts 30,000 US residents, and about 75,000 people around the world.
Royalty Pharma announced yesterday that it will buy royalties on Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) cystic fibrosis treatments from the Cystic Fibrosis Foundation for $3.3 billion in cash. This deal is believed to be the largest financial return ever made by any charitable organization working to find cures for medical diseases.
Vertex Pharmaceuticals Inc released corrected data involving its cystic fibrosis treatments on Tuesday that lowered the number of patients who showed certain levels of improved lung function, sending its ...
Miami (AFP) - A combination of two drugs has shown promise toward improving the health of people with the most common form of the incurable lung disease known as cystic fibrosis, researchers said Sunday.
By Small Pharma Analyst:Vertex (VRTX) is a 25-year old biopharma company that has had more than its share of ups and downs over the years - and yet another company-defining event is just around the corner.